The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Key Points Pfizer’s earnings and stock price soared in early pandemic days thanks to its coronavirus treatment and ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Pfizer 's (PFE -0.28%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

We upgraded the rating for Pfizer (PFE) stock, citing positive trends within the company and in the market, despite recent drop after Q2 earnings. Learn more here.

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street's revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer's future growth ...

Firstly, let us look at Pfizer’s stock performance in recent years. PFE stock has faced a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 45% ...